ArticleCancer medicine2026
Survival Trends and Prognostic Modeling in ALK-Positive Anaplastic Large Cell Lymphoma: A Population-Based Study in the Brentuximab Vedotin Era.
Article in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
backgroundALK-positive anaplastic large cell lymphoma (ALK+ ALCL) is a rare subtype of peripheral T-cell lymphoma with traditionally favorable prognosis. The introduction of brentuximab vedotin (BV) has significantly impacted treatment outcomes, but the long-term survival trends and predictive factors for this population remain underexplored.
methodsA total of 1548 patients diagnosed with ALK+ ALCL between 2004 and 2017 were identified from the Surveillance, Epidemiology, and End Results (SEER) database. Patients were categorized into two eras: pre-BV (2004-2010, n = 795) and post-BV (2011-2017, n = 753). Overall survival (OS) was compared between eras. A random survival forest (RSF) model was constructed to identify prognostic factors and stratify survival risk in the post-BV cohort.
resultsOS significantly improved in the post-BV era (HR = 0.68, 95% CI: 0.58-0.81, p < 0.001), with the 5-year OS increasing from 59.3% to 72.3%. The RSF model identified age, Ann Arbor stage, primary site, B symptoms, and radiotherapy as key prognostic factors, showing good discrimination with C-indices of 0.775 (training cohort) and 0.728 (testing cohort). Notably, radiotherapy was found to be a protective factor. The model effectively stratified patients into high-risk (5-year OS: 49.3%) and low-risk (86.0%) groups.
conclusionThe introduction of BV has significantly improved real-world survival in ALK+ ALCL. The RSF model enables individualized risk stratification and may support future precision treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.